<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • There are no suggestions because the search field is empty.

On Demand Webinar

Closing the Translational Gap - Biomarker Case Studies from Preclinical to Clinical Trial Testing 

Promising preclinical results don’t always become meaningful patient benefit. Non-representative models, inconsistent assays, cross-species differences, and unclear clinical decisions all widen the translational gap. For antibody-drug conjugate (ADC) programs, the stakes are even higher. Target expression, off-tumor safety, and patient selection all need to be understood before you reach the clinic.

Watch a preview:

Crown Bioscience brings together more than 1,000 cell lines and over 5,000 characterized models, including more than 2,700 PDX models. These are supported by in-house bioinformatics, multi-omics profiling, and biomarker testing that harmonizes across our global sites. The result is baseline data you can use to select the right model, the right indication, and ultimately the right patient.

In this webinar, you will see how Crown Bioscience’s integrated platform supports biomarker discovery and validation from early preclinical research through clinical trial testing. Using ADC development as the primary example, the session covers validated IHC assays, tissue microarray screening, digital pathology, and proteomics.

It also introduces Model AI, our new AI agent for exploring Crown Bioscience data. Real-world case studies show how these tools turn complex data into confident program decisions.

What You’ll Learn:

  • Why the translational gap persists, and how representative models, reproducible assays, and clear clinical decision criteria help close it
  • How our bioinformatics team turns efficacy and multi-omics data into biologically interpretable biomarker hypotheses, including response and resistance mechanisms
  • How more than 70 validated human tumor-associated antigen (TAA) IHC assays, off-the-shelf TMAs, and multiplex panels support ADC target selection, off-tumor safety assessment, and precision model selection
  • How PDX and organoid models show highly correlated target expression (R² > 0.9), with case studies including GUCY2C, c-MET, and Nectin-4 ADCs and CD3-based T cell engagers
  • How digital pathology and AI-based scoring can quantify target expression at single-cell resolution and predict response
  • How proteomics, including targeted protein degradation studies, and CAP/CLIA-accredited laboratories in the US and China support the path from discovery to clinical trial testing

About the Presenter:

julieJulie Ann Mayer, PhD, Vice President, Global Biomarker Platform, Crown BioscienceDr. Julie Mayer joined Crown Bioscience from NeoGenomics Laboratories, where she served as Vice President of Molecular Strategy, overseeing the R&D organization largely focused on developing comprehensive, high-throughput NGS and novel technology/applications.

Dr. Mayer has held progressive scientific and leadership roles spanning R&D and Operations at several molecular diagnostics companies, including NeoGenomics Laboratories, Biocept Inc., Navigate BioPharma Services (a Novartis subsidiary), Genoptix (a former Novartis subsidiary), Menarini Silicon Biosystems, and Quest. She has extensive precision medicine experience, having developed, validated, and launched >50 diagnostic assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories.

Before joining industry, Dr. Mayer received her post-doctoral training in translational breast cancer research at Baylor College of Medicine and in clinical cancer prevention at MD Anderson Cancer Center.

Dr. Mayer obtained her Ph.D in Pathology and Master’s of Science in Experimental and Molecular Pathology both from the University of Southern California, and a Bachelor’s degree in Biology from the University of California Riverside.

Watch Now

Your privacy is important to us.
We'll never share your information.